Analysis of Patients with NET G1/G2 Neuroendocrine Tumors of the Small Intestine in the Course of Carcinoid Heart Disease-A Retrospective Study

被引:1
|
作者
Konsek-Komorowska, Sonia J. J. [1 ]
Peczkowska, Mariola [2 ]
Kolasinska-Cwikla, Agnieszka D. D. [3 ]
Cichocki, Andrzej [3 ]
Konka, Marek [2 ]
Roszkowska-Purska, Katarzyna [3 ]
Cwikla, Jaroslaw B. [1 ,4 ]
机构
[1] Univ Warmia & Mazury, Sch Med, Dept Cardiol & Internal Med, Coll Med, PL-10082 Olsztyn, Poland
[2] Cardinal Stefan Wyszynski Natl Inst Cardiol, PL-04628 Warsaw, Poland
[3] Maria Sklodowska Curie Natl Res Inst Oncol, PL-02034 Warsaw, Poland
[4] Diagnost & Therapeut Ctr Gammed, PL-02351 Warsaw, Poland
关键词
carcinoid heart disease; carcinoid syndrome; neuroendocrine neoplasms of the small intestine; overall survival; primary tumor resection; POLISH NETWORK; GUIDELINES; NEOPLASMS; CLASSIFICATION; PROGRESSION; DIAGNOSIS; PROGNOSIS; MIDGUT;
D O I
10.3390/jcm12030790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neuroendocrine neoplasms of the small intestine (SI-NENs) are one of the most commonly recognized gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Carcinoid heart disease (CHD) is the primary cause of death in patients with the carcinoid syndrome (CS). The aim of this retrospective study was to evaluate possible factors impacting upon overall survival (OS) in subjects with both neuroendocrine tumors (NETs) G1/G2 of the small intestine (SI-NET) and CHD. Enrolled in our study of 275 patients with confirmed G1/G2 SI-NET, were 28 (10%) individuals with CHD. Overall survival was assessed using the Kaplan-Meier method. The Cox-Mantel test was used to determine how OS varied between groups. A Cox proportional hazards model was used to conduct univariate analyses of predictive factors for OS and estimate hazard ratios (HRs). Of the 28 individuals with confirmed carcinoid heart disease, 12 (43%) were found to have NET G1 and 16 (57%) were found to have NET G2. Univariate analysis revealed that subjects with CHD and without resection of the primary tumor had a lower OS. Our retrospective study observed that patients who presented with CHD and without resection of primary tumor had worse prognosis of survival. These results suggest that primary tumors may need to be removed when feasible, but further research is needed. However, no solid recommendations can be issued on the basis of our single retrospective study.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Surgical Treatment of Small Intestinal Neuroendocrine Tumors G1/G2
    Selberherr, Andreas
    Niederle, Martin B.
    Niederle, Bruno
    VISCERAL MEDICINE, 2017, 33 (05) : 340 - 343
  • [2] FOLFOX in pancreatic G1 and G2 neuroendocrine tumors
    Bengueddache, A.
    Kehili, H.
    Tidjane, A.
    Remini, A.
    Boudjnane, N.
    Tabeti, B.
    Tilioua, O.
    Bereksi-Reguig, F.
    Zaoui, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 215 - 215
  • [3] Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
    Zappi, Arianna
    Persano, Irene
    Galvani, Linda
    Parlagreco, Elena
    Andrini, Elisa
    Campana, Davide
    Brizzi, Maria Pia
    Lamberti, Giuseppe
    La Salvia, Anna
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [4] Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors
    Nyiro, G.
    Szeredas, B.
    Vekony, B.
    Borka, K.
    Zalatnai, A.
    Dezso, K.
    Kovalszky, I
    Igaz, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 36 - 36
  • [5] miRNA Expression Profiling in G1 and G2 Pancreatic Neuroendocrine Tumors
    Nyiro, Gabor
    Szeredas, Balint Kende
    Decmann, Abel
    Herold, Zoltan
    Vekony, Balint
    Borka, Katalin
    Dezso, Katalin
    Zalatnai, Attila
    Kovalszky, Ilona
    Igaz, Peter
    CANCERS, 2024, 16 (14)
  • [6] Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study
    Ida, Hanae
    Honma, Yoshitaka
    Hirano, Hidekazu
    Shoji, Hirokazu
    Iwasa, Satoru
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Fukuda, Takahiro
    Boku, Narikazu
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 573 - 578
  • [7] Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study
    Hanae Ida
    Yoshitaka Honma
    Hidekazu Hirano
    Hirokazu Shoji
    Satoru Iwasa
    Natsuko Okita
    Atsuo Takashima
    Ken Kato
    Takahiro Fukuda
    Narikazu Boku
    Investigational New Drugs, 2019, 37 : 573 - 578
  • [8] Can Ampullary G1 and G2 Neuroendocrine Tumors Be Cured by Endoscopic Papillectomy?
    Zhang, Wengang
    Chai, Ningli
    Linghu, Enqiang
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [9] Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome
    Konsek-Komorowska, Sonia J.
    Peczkowska, Mariola
    Kolasinska-Cwikla, Agnieszka D.
    Konka, Marek
    Chrapowicki, Eryk
    Cwikla, Jaroslaw B.
    MEDICINA CLINICA, 2022, 159 (02): : 85 - 89
  • [10] Prognostic Relevance of Aberrant DNA Methylation in G1 and G2 Pancreatic Neuroendocrine Tumors
    Stefanoli, Michele
    La Rosa, Stefano
    Sahnane, Nora
    Romualdi, Chiara
    Pastorino, Roberta
    Marando, Alessandro
    Capella, Carlo
    Sessa, Fausto
    Furlan, Daniela
    NEUROENDOCRINOLOGY, 2014, 100 (01) : 26 - 34